Mitochondria-Specific Nano-Emulsified Therapy for Myocardial Protection Against Doxorubicin-Induced Cardiotoxicity

  • Amy Faulk
  • Volkmar Weissig
  • Tamer Elbayoumi
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 991)

Abstract

The quinonoid anthracycline, doxorubicin (Adriamycin), is a widely used potent antineoplastic agent, showing the broadest spectrum of antineoplastic activity against various types of solid carcinomas, hematological malignancies, and soft tissue sarcomas. Unfortunately, the clinical use of doxorubicin is associated with cumulative dose-limiting cardiac toxicity, manifested as cardiomyopathy and congestive heart failure, in which mitochondrial damage is primarily implicated. Free radical formation at and inside mitochondria, in particular the rise of reactive oxygen species (ROS), has long been hypothesized as the common mechanism by which doxorubicin causes this severe cardiotoxicity. Concomitant with newly gained insights into the central role of mitochondria in programmed cell death (apoptosis), irreversible destabilization of mitochondrial membrane permeability transition (mMPT), and disruption of mitochondrial Ca2+ homeostasis have been strongly implicated in triggering myocardial apoptosis, due to accumulated doxorubicin dosing.

Hence, our current protocols show the development of mitochondria-targeted nanoemulsions (NEs), based on previous work using nano-vesicle surface modification with mitochondriotropic triphenylphosphonium (TPP) ligands, which have successfully been demonstrated to target drug and DNA-loaded liposomes to mitochondria in living mammalian cells. Our mitochondria-specific TPP-coated therapeutic NEs are prepared using tocopherol oxygen scavengers and are highly loaded with mitochondria-stabilizing therapeutics, namely, cyclosporine A (CsA). Our targeted nano-formulation, proposed as injectable adjuvant therapy, is capable of reaching target affected mitochondria in sufficient therapeutic concentration, in order to revert or at least limit oxidative and non-oxidative doxorubicin-induced mitochondrial damage, manifested in affected cardiac muscle tissues, Based on several encouraging studies using in vitro model rat cardiac muscle, H9C2 cardiomyocytes, and vascular media tunica media, A10, cell cultures, our proof-of principal mitochondriotropic nano-therapy demonstrates strong potential to improve not only the cardiac safety profile, through concurrent rescue administration of targeted nano-encapsulated FDA-approved cyclosporine A (CSA), but also dosing range of the currently available potent adriamycin/doxorubicin-based chemotherapy regimens.

Key words

Anthracycline Mitochondrial damage Mitochondriotropic Cyclosporine A Cardio­myocytes Chaotropic effect Apoptosis 

References

  1. 1.
    Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302–314CrossRefGoogle Scholar
  2. 2.
    Allen A (1992) The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 19:529–542Google Scholar
  3. 3.
    Doroshow JH (1983) Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43:460–472Google Scholar
  4. 4.
    DiPiro JT, Talbert RL (2002) Pharmacotherapy: a pathophysiologic approach, 5th edn. McGraw-Hill, LondonGoogle Scholar
  5. 5.
    Gabizon AA, Lyass O, Berry GJ, Wildgust M (2004) Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 22:663–669CrossRefGoogle Scholar
  6. 6.
    Doroshow JH (1983) Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res 43:4543–4551Google Scholar
  7. 7.
    Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41:389–405CrossRefGoogle Scholar
  8. 8.
    Wallace KB (2007) Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 7:101–107CrossRefGoogle Scholar
  9. 9.
    Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB (2001) Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 61:771–777Google Scholar
  10. 10.
    Patel NR, Hatziantoniou S, Georgopoulos A, Demetzos C, Torchilin VP, Weissig V, D’Souza GG (2010) Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J Liposome Res 20:244–249CrossRefGoogle Scholar
  11. 11.
    Boddapati SV, D’Souza GG, Erdogan S, Torchilin VP, Weissig V (2008) Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett 8:2559–2563CrossRefGoogle Scholar
  12. 12.
    Weissig V, Boddapati SV, Cheng SM, D’Souza GG (2006) Liposomes and liposome-like vesicles for drug and DNA delivery to mitochondria. J Liposome Res 16:249–264CrossRefGoogle Scholar
  13. 13.
    Boddapati SV, Tongcharoensirikul P, Hanson RN, D’Souza GG, Torchilin VP, Weissig V (2005) Mitochondriotropic liposomes. J Liposome Res 15:49–58Google Scholar
  14. 14.
    Ganta S, Amiji M (2009) Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6:928–939CrossRefGoogle Scholar
  15. 15.
    Mu L, Elbayoumi TA, Torchilin VP (2005) Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int J Pharm 306:142–149CrossRefGoogle Scholar
  16. 16.
    Elbayoumi TA, Pabba S, Roby A, Torchilin VP (2007) Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res 17:1–14CrossRefGoogle Scholar
  17. 17.
    Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP (2004) Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release 100:135–144CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Amy Faulk
    • 1
  • Volkmar Weissig
    • 1
  • Tamer Elbayoumi
    • 1
  1. 1.Department of Pharmaceutical SciencesMidwestern University College of PharmacyGlendaleUSA

Personalised recommendations